Oculis Set to Engage at the Stifel 2024 Healthcare Conference
Oculis Holding AG (NASDAQ: OCS), a forward-thinking biopharmaceutical entity located in Switzerland, is gearing up to participate in the Stifel 2024 Healthcare Conference. This prominent event, scheduled for November 18-19, promises an engaging platform for industry discussions and innovative insights.
A Fireside Chat with Oculis Leadership
The Chief Financial Officer, Sylvia Cheung, will represent Oculis during a special fireside chat on the first day of the conference, precisely at 3:35 PM ET. This session will provide attendees with valuable perspectives from the management team about the company's vision and future projects.
Connecting with Investors
During the conference, Oculis aims to foster connections by offering one-on-one meetings with interested investors. Individuals keen on learning about the latest developments are encouraged to reach out to their Stifel representatives to arrange these exclusive discussions.
Live Broadcast of Key Presentations
For those unable to attend in person, Oculis will facilitate a live webcast of the fireside chat, allowing a broader audience to engage with their insights and innovations. Details regarding access to the webcast will be made available through Oculis’ website, ensuring no one misses out on this opportunity.
About Oculis and Its Mission
At its core, Oculis is dedicated to making significant advancements in eye care. The company boasts a varied pipeline of unique product candidates designed to address pressing health concerns related to vision. Notably, OCS-01 stands out as a promising topical eye drop formulation aimed at combating diabetic macular edema (DME) and managing inflammation post-cataract surgery.
Innovative Product Pipeline
Alongside OCS-01, the company is advancing licaminlimab (OCS-02), a topical biologic designed for treating dry eye disease and non-infectious anterior uveitis, and OCS-05, targeted toward neuroprotection for acute optic neuritis. Oculis remains committed to enhancing patient care globally through its innovative approach and strategic developments.
A Vision for the Future
Headquartered in Switzerland with operational reach in the U.S. and Iceland, Oculis is strategically positioned in the biopharmaceutical industry. The company is led by a robust management team with extensive industry experience, reinforcing Oculis’ reputation as a trusted innovator in eye care.
Join Oculis on Their Journey
As Oculis prepares for this key industry event, there’s a sense of excitement around its ongoing commitment to enhancing the quality of life for patients through innovative eye care solutions. To stay updated on Oculis’ progress and participate in its journey, further information is accessible via the company’s website.
Frequently Asked Questions
What is the aim of Oculis at the Stifel 2024 Healthcare Conference?
Oculis aims to provide insights into its innovative product pipeline and engage with investors during this prominent event.
Who will represent Oculis at the conference?
Sylvia Cheung, the Chief Financial Officer, will represent Oculis by participating in a fireside chat.
How can interested investors connect with Oculis?
Investors can request one-on-one meetings with Oculis by contacting their Stifel representatives.
Is there a way to watch the fireside chat live?
Yes, Oculis will provide a live webcast of the fireside chat accessible through their website.
What products are being highlighted by Oculis?
Oculis will showcase products like OCS-01, a topical eye drop for DME, and OCS-02 for dry eye disease among others.
